| Keywords: |
cancer chemotherapy; acute granulocytic leukemia; nonhuman; conference paper; alpha interferon; cytarabine; neoplasms; cell division; interleukin 2; cancer prevention; melanoma; erythropoietin; granulocyte macrophage colony stimulating factor; interleukin 4; cell differentiation; chronic myeloid leukemia; gene expression regulation; dimethyl sulfoxide; myelodysplastic syndrome; gamma interferon; neuroblastoma; vitamin d; breast carcinoma; dactinomycin; gene control; lung carcinoma; 5 aza 2' deoxycytidine; protein kinase c; kaposi sarcoma; isotretinoin; oncogene c myc; malignant transformation; granulocyte colony stimulating factor; retinoic acid; keratinocyte growth factor; uterine cervix carcinoma; butyric acid; dysplasia; leukoplakia; uterine cervix dysplasia; colecalciferol; hexamethylenebisacetamide; phospholipase c; human; priority journal; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; revertant; calcimycin; tiazofurin; 8 chloroadenosine 3',5' phosphate; arotinoid; mofarotene
|
